An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19
Open Access
- 20 April 2020
- journal article
- editorial
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 150 (1718), w20262
- https://doi.org/10.4414/smw.2020.20262
Abstract
A recent open-label study claimed that hydroxychloroquine and azithromycin represent promising new options for the treatment of SARS-CoV-2. This re-analysis reveals severe limitations in the methodology of this study, including ambiguous inclusion/exclusion of participant data and inconsistent analysis techniques, and yielded nonsignificant differences between control and treatment groups across any treatment days.Keywords
This publication has 6 references indexed in Scilit:
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatologyNature Reviews Rheumatology, 2020
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBioScience Trends, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Primer Design Assistant (PDA): a web-based primer design toolNucleic Acids Research, 2003